Topical carmustine (BCNU) in the treatment of mycosis fungoides.
The University of California, San Francisco (UCSF), experience with topical carmustine (BCNU) in the treatment of approximately 200 patients with mycosis fungoides (MF) is summarized. Topical BCNU is an effective treatment for patch- and early plaque-stage MF. Side-effects are usually not a major deterrent to continuation of therapy.
Zackheim
Herschel S
HS
Department of Dermatology, University of California-San Francisco, California, Menlo Park 94025, USA. hszackheim@orca.ucsf.edu
D000287:Administration, Topical; D002330:Carmustine / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009182:Mycosis Fungoides / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D009367:Neoplasm Staging; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
D002330:Carmustine